Scrape SBIR Bone Repair Patent & Award Database for Phase II Applicants
- Organization
- NSF SBIR Phase II commercialization plan requirement without competitive intelligence tools
- Sector
- SBIR-funded bone repair companies needing competitive analysis for Phase II applications
- Location
- Location unspecified
Source reference
Executive summary
Current state
NSF awarded $305K SBIR Phase I funding to CYTROGEN for Gelatrix, a light-curable bone adhesive, creating a research-funded entity with technical validation capital but zero commercial infrastructure, manufacturing partnerships, or market access pathways.
Market catalyst
CYTROGEN has SBIR funding but lacks competitive intelligence for their Phase II commercialization plan. Every SBIR biomaterial company faces the same repetitive research burden: manually searching patents and competitor awards to position their technology for Phase II review.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.